# Phase 3 leukemia trials recruiting: 75 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 75 trials in phase 3 for leukemia that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 leukemia trials: 75 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/leukemia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 75
- Recruiting or not yet: 75
- Read on: November 19, 2026

## Trials

The 25 newest of 75, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07925190 | A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Recruiting | Acute Myeloblastic Leukemia | 318 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925190) |
| October 29, 2026 | NCT07905183 | A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs | Enliven Therapeutics | Phase 3 | Recruiting | Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, Chronic Phase Chronic... | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905183) |
| October 21, 2026 | NCT07885293 | A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Chronic Myeloid Leukemia | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885293) |
| August 12, 2026 | NCT07761702 | Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML | Shanghai Jiao Tong University School of Medicine | Phase 3 | Not yet recruiting | AML (Acute Myelogenous Leukemia) | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761702) |
| August 7, 2026 | NCT07753369 | A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of... | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753369) |
| July 29, 2026 | NCT07735117 | Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML | Ruijin Hospital | Phase 3 | Not yet recruiting | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735117) |
| July 20, 2026 | NCT07712848 | DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML | The Second Affiliated Hospital of Kunming Medical University | Phase 3 | Recruiting | AML (Acute Myeloid Leukemia) | 291 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712848) |
| July 7, 2026 | NCT07686965 | Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at... | Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | Not yet recruiting | Acute Myeloid Leukemia (AML), Maintenance Treatment, Hematopoetic Stem Cell Transplantation | 191 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686965) |
| June 16, 2026 | NCT07649525 | Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level | University of Leeds | Phase 3 | Recruiting | Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | 1,226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649525) |
| June 15, 2026 | NCT07648264 | Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting... | CSL Behring | Phase 3 | Recruiting | Secondary Immune Deficiency | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648264) |
| May 12, 2026 | NCT07582432 | A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency... | Grifols Biologicals, LLC | Phase 3 | Recruiting | Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582432) |
| April 7, 2026 | NCT07516093 | Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL | Nurix Therapeutics, Inc. | Phase 3 | Recruiting | B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 620 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516093) |
| April 7, 2026 | NCT07514936 | Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | Chinese PLA General Hospital | Phase 3 | Recruiting | Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07514936) |
| April 3, 2026 | NCT07509151 | Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated... | AstraZeneca | Phase 3 | Recruiting | Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509151) |
| March 31, 2026 | NCT07504458 | Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | Quetzal Therapeutics | Phase 3 | Recruiting | Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07504458) |
| March 24, 2026 | NCT07489755 | TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients | Shenzhen TargetRx Co., Ltd. | Phase 3 | Not yet recruiting | Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489755) |
| March 20, 2026 | NCT07486479 | Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | The First Affiliated Hospital of Soochow University | Phase 3 | Not yet recruiting | Acute Myeloid Leukemia (AML) | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07486479) |
| March 18, 2026 | NCT07478991 | Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) | PETHEMA Foundation | Phase 3 | Recruiting | Acute Myeloid Leukemia, Adult | 376 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07478991) |
| March 13, 2026 | NCT07469046 | VAH vs VA in Newly Diagnosed Elderly AML | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 3 | Not yet recruiting | Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years) | 308 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07469046) |
| March 11, 2026 | NCT07463651 | MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib | The First Affiliated Hospital of Soochow University | Phase 3 | Recruiting | Acute Myeloid Leukemia (AML), FLT3-ITD Mutation, Allogeneic Hematopoietic Cell Transplantation (HCT), Maintenance... | 594 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07463651) |
| February 12, 2026 | NCT07407660 | Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With... | Peking University People's Hospital | Phase 3 | Not yet recruiting | Acute Myeloid Leukemia | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407660) |
| February 12, 2026 | NCT07407140 | VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML | Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | Not yet recruiting | AML, Adult | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407140) |
| January 15, 2026 | NCT07342478 | ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL | Newave Pharmaceutical Inc | Phase 3 | Recruiting | CLL / SLL, CLL (Chronic Lymphocytic Leukemia), CLL, Refractory, CLL, Relapsed, SLL (Small Lymphocytic Lymphoma), SLL... | 306 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07342478) |
| January 7, 2026 | NCT07321652 | Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL | Alliance for Clinical Trials in Oncology | Phase 3 | Recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | 466 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07321652) |
| December 22, 2025 | NCT07296445 | A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy... | SDK Therapeutics, Inc. | Phase 3 | Not yet recruiting | Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07296445) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 4 |
| Institute of Hematology & Blood Diseases Hospital, China | 4 |
| Shanghai Jiao Tong University School of Medicine | 3 |
| The First Affiliated Hospital of Soochow University | 3 |
| Stichting Hemato-Oncologie voor Volwassenen Nederland | 3 |
| Children's Oncology Group | 3 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 2 |
| Peking University People's Hospital | 2 |
| Ruijin Hospital | 2 |
| [Ascentage Pharma Group Inc.](https://specstream.ai/data/clinical-trials/company/ascentage-pharma-group-inc) | 2 |
| [Sunshine Lake Pharma Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sunshine-lake-pharma-co-ltd) | 1 |
| Chinese PLA General Hospital | 1 |
| National Research Center for Hematology, Russia | 1 |
| German CLL Study Group | 1 |
| Vastra Gotaland Region | 1 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 1 |
| University of Ulm | 1 |
| Loxo Oncology, Inc. | 1 |
| The Second Affiliated Hospital of Kunming Medical University | 1 |
| [Il-Yang Pharm. Co., Ltd.](https://specstream.ai/data/clinical-trials/company/il-yang-pharm-co-ltd) | 1 |
| University of Leeds | 1 |
| Alliance for Clinical Trials in Oncology | 1 |
| Shenzhen TargetRx Co., Ltd. | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
| King Faisal Specialist Hospital & Research Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 29 |
| United States | 29 |
| Spain | 22 |
| Germany | 21 |
| France | 20 |
| Italy | 19 |
| United Kingdom | 19 |
| Australia | 18 |
| Belgium | 17 |
| Canada | 15 |
| Poland | 13 |
| Netherlands | 12 |
| Austria | 11 |
| Sweden | 10 |
| Brazil | 10 |
| Czechia | 10 |
| South Korea | 10 |
| Japan | 10 |
| Denmark | 9 |
| Israel | 9 |
| Turkey (Türkiye) | 9 |
| Lithuania | 8 |
| Norway | 8 |
| Argentina | 8 |
| New Zealand | 8 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hydraulic repair companies in the United States](https://specstream.ai/data/businesses/hydraulic-repair-companies/united-states)
- [Architecture firms in the United States](https://specstream.ai/data/businesses/architecture-firms/united-states)
- [Medical law firms in the United States](https://specstream.ai/data/businesses/medical-law-firms/united-states)
- [Broadcast media production companies in the United States](https://specstream.ai/data/businesses/broadcast-media-production-companies/united-states)
- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Damage restoration companies in the United States](https://specstream.ai/data/businesses/damage-restoration-companies/united-states)
